Skip to content

Anxiety: all studies

Page 217 of 774: studies 2,161 to 2,170 of 7,737, newest first. Back to the anxiety overview

Research

Mindfulness, coping, and optimism as mechanisms of change in the 3RP-NF intervention.

Journal of Clinical Psychology February 1, 2024 Victoria A Grunberg, Jafar Bakhshaie, Heena R Manglani et al. 4 citations

Neurofibromatosis (NF) is chronic neurogenetic condition that increases risk for poor quality of life, depression, and anxiety. Given the lack of biomedical treatments, we developed the "Relaxation Response Resiliency for NF" (3RP-NF) program to improve psychosocial outcomes among adults with NF. To move toward effectiveness testing, we must understand mechanisms that explained treatment...

Preliminary evidence of psychological improvements and increased maternal-fetal attachment associated with a mindfulness sleep programme: secondary analysis of uncontrolled data in 11 pregnant women with insomnia disorder.

Journal of Sleep Research February 1, 2024 David A Kalmbach, Anthony N Reffi, Jason C Ong et al. 9 citations

Treating insomnia during pregnancy improves sleep and depressed mood. However, given well-established links between poor sleep and a broad spectrum of adverse maternal outcomes, the benefits of insomnia care may reach beyond sleep and depression. The present study evaluated the preliminary efficacy of 'Perinatal Understanding of Mindful Awareness for Sleep' (PUMAS)-a mindfulness sleep programme...

Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists

Current Psychiatry Research and Reviews January 21, 2024 Payal Ghosh, Debjeet Sur 1 citation

: Psychedelics are currently being examined once more as potential remedies for untreatable biological illnesses after decades of research problems. They are frequently regarded to be physically safe and do not frequently lead to dependency or addiction. The use of psychedelic substances in the treatment of mental illness and the adoption of the Substance Act of 1970 has classified psychedelic...

Psilocybe cubensis extract potently prevents fear memory recall and freezing behavior in short- but not long-term in a rat model of posttraumatic stress disorder.

Behavioral Neuroscience January 18, 2024 Zahra Ghofrani-Jahromi, Sarah Nouri-Darehno, Mehrsa Rahimi-Danesh et al. 22 citations

Psilocybe cubensis is a species of psilocybin mushroom (magic mushroom) of moderate potency whose principal active compounds are psilocybin and psilocin. Recent studies have shown the significant procognitive and mood-enhancer effects of Psilocybe cubensis. However, evidence is so limited, especially in preclinical studies. We aimed to investigate the effect of Psilocybe cubensis extract on...

Nightmare experiences and perceived ethnic discrimination amongst female university students in the United Arab Emirates: a cross‐sectional study

Journal of Sleep Research January 17, 2024 María Campo-Redondo, Gabriel Andrade

Perceived ethnic discrimination is known to be associated with anxiety and depression, and in turn, anxiety and depression are known to be associated with nightmare frequency and distress. This elicits a question: is perceived ethnic discrimination associated with nightmare frequency and distress? In this study, 179 female university students from the United Arab Emirates were assessed to...

Abstract C001: A pilot study of palliadelic treatment with psilocybin to reduce psychological distress and improve quality of life in patients with advanced pancreatic adenocarcinoma

Cancer Research January 16, 2024 Kelsey Klute, Lou Lukas, Soonjo Hwang et al. 2 citations

Abstract Background: Psychological distress is a common reaction to a cancer diagnosis and its treatment. Distress impacts quality of life, adherence to treatment, decision making and survival. Patients with pancreatic adenocarcinoma (PDAC) experience exceptionally high rates of psychological distress, most commonly depression, anxiety and suicidality. Psilocybin, a serotonergic psychedelic...

EFEITOS PSICOLÓGICOS DA PSILOCIBINA EM PORTADORES DE CÂNCER TERMINAL: Uma revisão de escopo

Psicologia e Saúde em Debate January 10, 2024 Leonardo Hercílio Florêncio Silva, Júnia Aparecida Laia Da Mata, Sabrina Stefanello et al.

Psilocybin is a natural substance with hallucinogenic properties that has recently been used in the field of health. It is an alkaloid that, when associated with psychotherapy, has shown benefits in the treatment of depression and anxiety. This study aims to analyze the current state of knowledge about the psychological effects of psilocybin in patients with terminal cancer. The method used was...

Effects of MDMA-assisted therapy for PTSD on self-experience

PLoS One January 10, 2024 Rachel Yehuda, Leah Bedrosian, Charlotte Harrison et al. 52 citations

Introduction There is a resurgence of interest in the therapeutic potential of psychedelic substances such as 3,4-methylenedioxymethamphetamine (MDMA). Primary findings from our randomized, double-blind, placebo-controlled, multi-site Phase 3 clinical trial of participants with severe PTSD (NCT03537014) showed that MDMA-assisted therapy induced significant attenuation in the...

Corrigendum to “Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis”. [J. Affect. Disord., 322 (2023), 194–204]

Journal of Affective Disorders January 5, 2024 Kwonmok Ko, Emma I Kopra, Anthony J. Cleare et al. 1 citation correction

The authors wish to express their regret regarding an error in the publication of the original article. In Table 3, titled “Psilocybin studies on depressive disorders,” specifically in the fourth row related to the study conducted by Carhart-Harris et al. (2016), the main results column inaccurately presented the Cohen's d figure, which included data from Carhart-Harris et al. (2018) that...

DOI: 10.1016/j.jad.2023.10.159 (opens in new tab) Anxiety Affect linguistics Clinical psychology Depressive symptoms +2

The antidepressant effects of vaporized N,N-Dimethyltryptamine: a preliminary report in treatment-resistant depression

medRxiv January 4, 2024 Marcelo Falchi-Carvalho, Handersson Barros, Raynara Bolcont et al. 5 citations preprint

Abstract Introduction N,N-Dimethyltryptamine (DMT), a naturally occurring psychedelic tryptamine contained in the indigenous ayahuasca brew has shown antidepressant effects. This Phase 2a clinical trial investigates for the first time the efficacy of isolated DMT in treatment-resistant depression (TRD). Methods Six TRD patients participated in an open-label, fixed-order, dose-escalation study,...